Gamida Cell Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMDA research report →
About the company
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies.
- CEO
- Abigail L. Jenkins
- IPO
- 2018
- Employees
- 143
- HQ
- Jerusalem, IL
Price Chart
- Market Cap
- $4.34M
- P/E
- -0.08
- P/S
- 2.43
- P/B
- -1.65
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
- Gross Margin
- -94.96%
- Op Margin
- -4094.06%
- Net Margin
- -3531.17%
- ROE
- 1148.30%
- ROIC
- -86.17%
- Revenue
- $1.78M · 0.00%
- Net Income
- $-62,996,000 · 59.19%
- EPS
- $-0.42 · 82.64%
- Op Income
- $-73,038,000
- FCF YoY
- -4.46%
- 52W High
- $0.04
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 1.03
- Avg Volume
- 21.71M
Get TickerSpark's AI analysis on GMDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 24 | MOCH KENNETH I | other | 200,000 |
| Jan 31, 24 | WILLS STEPHEN T | other | 200,000 |
| Jan 31, 24 | Tomasello Shawn | other | 200,000 |
| Jan 31, 24 | ADAMS JULIAN | other | 200,000 |
| Jan 31, 24 | Simantov Ronit | other | 480,319 |
| Jan 31, 24 | Borrello Ivan M. | other | 200,000 |
| Jan 31, 24 | Patterson Joshua F. | other | 480,319 |
| Jan 31, 24 | Korfin Michele Ilene | other | 480,319 |
| Oct 19, 23 | Jenkins Abigail L. | other | 109,013 |
| Oct 19, 23 | Jenkins Abigail L. | other | 217,954 |
Our GMDA coverage
Recent articles, reports, and earnings notes.
No research on GMDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GMDA report →Similar companies
Peers in the same neighborhood.